EUCTR2011-005452-34-SE进行中（未招募）不适用
A Phase 4, Randomised, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Referance Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 542
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The subject will not be considered eligible for the study without meeting
- •all of the inclusion criteria below. The subject cannot be randomized
- •before all inclusion criteria (including test results) are confirmed.
- •1. Subject must be 13-17 years of age, inclusive, at the time of consent.
- •2. Subject must weigh more than 79.5lb (36kg).
- •3. Subject's parent or legally authorized representative (LAR) must
- •provide signature of informed consent, and there must be documentation
- •of assent (if applicable) by the subject indicating that the subject is
- •aware of the investigational nature of the study and the required
- •procedures and restrictions in accordance with the ICH Good Clinical
- •Practice (GCP) Guideline E6 (1996) and applicable regulations before
- •completing any study-related procedures.
- •4. Subject and parent/LAR are willing and able to comply with all of the
- •testing and requirements defined in the protocol, including oversight of
- •morning dosing. Specifically, the parent/LAR must be available at
- •approximately 7:00AM (±2 hours) to
- •dispense the dose of investigational product for the study duration.
- •5. Subject, who is a female, must not have a positive serum beta human
- •chorionic gonadotropin (ß-HCG) pregnancy test at the Screening Visit
- •(Visit -1) and must have a negative urine pregnancy test at the Baseline
- •Visit (Visit 0) and agree to comply with any applicable contraceptive
- •requirements of the protocol.
- •6. Subject meets the DSM-IV-TR criteria for a primary diagnosis of ADHD
- •based on a detailed psychiatric evaluation.
- •7. Subject has an ADHD-RS-IV total score =28 at the Baseline Visit (Visit 0).
- •8. Subject is functioning at an age-appropriate level intellectually, as
- •determined by the study Investigator.
- •9. Subject is able to swallow a capsule.
- •10. Subject's blood pressure measurements do not exceed the 90th
- •percentile for age, sex, and height at the Screening Visit (Visit -1) and
- •the Baseline Visit (Visit 0)
- •11. Subject is not completely satisfied with any aspect of their current
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 542
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects are excluded from the study, if any of the following criteria are met at the Screening
- •Visit (Visit -1) or at the Baseline Visit (Visit 0).
- •The complete list of exclusion criteria are available in Section 4.2 of the Protocol
- •1. Subject has a current, controlled (with medications prohibited in this study) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any significant comorbid Axis II disorder or significant Axis I disorder (such as
- •post-traumatic stress disorder, psychosis, bipolar illness, pervasive developmental disorder, severe obsessive compulsive disorder, depressive or anxiety disorder) or other symptomatic manifestations that, in the opinion of the examining clinician, will contraindicate treatment with VYVANSE or CONCERTA or confound efficacy or safety assessments. Comorbid psychiatric diagnoses will be established with the Screening Visit (Visit -1) interview of the Kiddie–Schedule for Affective Disorders and Schizophrenia for School age Children–Present and Lifetime Version–Diagnostic Interview (K-SADS-PL) and additional modules if warranted by the results of the initial interview. Subjects may continue participation in a behavioral modification program during the study as long as they have been participating in the program for at least 1 month at the time of the Baseline Visit (Visit 0).
- •2. Subject meets DSM-IV-TR diagnosis of conduct disorder. Oppositional defiant disorder is not exclusionary.
- •3. Subject is considered a suicide risk in the opinion of the Investigator, has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. Subjects with intermittent passive suicidal ideation are not necessarily excluded based on the assessment of the Investigator.
- •4. Subject is underweight based on Centers for Disease Control and Prevention (CDC) body mass index (BMI)-for-age sex-specific values at the Screening Visit (Visit -1). Underweight is defined as a BMI <3rd percentile.
- •5. Subject is significantly overweight based on CDC BMI-for-age sex-specific values at the Screening Visit (Visit -1). Significantly overweight is defined as a BMI >97th percentile for this study.
- •6. Subject has a concurrent chronic or acute illness (such as severe allergic rhinitis or an infectious process requiring antibiotics), disability, or other condition that might confound the results of safety assessments conducted in the study or that might increase risk to the subject. Similarly, the subject will be excluded if he or she has any additional condition(s) that, in the Investigator’s opinion, would prohibit the subject from completing the study or would not be in the best interest of the subject. The additional conditions would include any significant illness or unstable medical condition
- •that could lead to difficulty complying with the protocol. Mild, stable asthma is not exclusionary.
- •7. Subject has a history of seizures (other than infantile febrile seizures), a chronic or current tic disorder, or a current diagnosis and/or a known family history of Tourette’s Disorder. Subject has a history of tics that are judged by the Investigator to be exclusionary.
- •8. Subject has a known history of symptomatic cardiovascular disease, advanced
- •arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm
- •abnormalities, coronary artery disease, or other serious cardiac problems that may place
- •him/her at increased vulnerability to the sympathomim
研究者
相似试验
进行中（未招募）
1 期
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivityMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-005452-34-ITShire Development LLC542
进行中（未招募）
不适用
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivityMedDRA version: 16.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-005452-34-DEShire Development LLC542
进行中（未招募）
不适用
A Study to assess the safety and efficacy of SPD489 compared with Concerta with a placebo reference arm on patients aged 13-17 years with Attention-Deficit/Hyperactivity DisorderAttention-deficit/hyperactivity disorder is a psychiatric disorder characterized by developmentally inappropriate degrees of inattentiveness, impulsivity, and hyperactivityMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2011-005452-34-HUShire Development LLC542
进行中（未招募）
1 期
The Effect of Benralizumab on Structural and Lung Function Changes in Patients with Severe AsthmaEUCTR2018-003391-13-SEAstraZeneca AB81
进行中（未招募）
1 期
Guselkumab versus Placebo for the Treatment of Psoriatic Arthritis Axial Disease in Bio-naive ParticipantsActive Psoriatic Arthritis Axial DiseaseMedDRA version: 21.0Level: LLTClassification code 10037160Term: Psoriatic arthritisSystem Organ Class: 100000004859EUCTR2021-000465-32-ITJANSSEN CILAG INTERNATIONAL NV405